Overall, divergent evidence indicates that AIS structural modification may be promoted by either APP, soluble Aβ or Aβ plaques, depending on the mouse model of AD in use, on the age of the mice (and thus the stage of amyloid pathology) and/or on the experimental procedures chosen. The gene discussed is APP; the disease is Alzheimer disease.